Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Izotropic ( (TSE:IZO) ) has issued an announcement.
Izotropic has announced the appointment of Dr. Kyle J. Myers, Dr. Alicia Toledano, and Mr. John DeLucia as consultants to lead the clinical study design and FDA regulatory submissions for its breast CT imaging system, IzoView. This strategic move aims to expedite access to IzoView’s advanced technology, which is intended to enhance breast cancer screening for asymptomatic women with dense breast tissue. The consultants bring extensive experience from leading roles in regulatory affairs and clinical study design, which is expected to strengthen Izotropic’s positioning in the medical imaging industry and potentially improve the company’s operations and market impact.
More about Izotropic
Izotropic Corporation is a medical device company focused on commercializing imaging-based products that leverage innovative technologies for improved screening, diagnosis, and treatment of breast cancers.
YTD Price Performance: 104.00%
Average Trading Volume: 71,672
Technical Sentiment Consensus Rating: Hold
Current Market Cap: $6.13M
See more data about IZO stock on TipRanks’ Stock Analysis page.
